June 27, 2011 Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer
June 23, 2011 Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue
May 26, 2011 Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
April 28, 2011 Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
March 31, 2011 Nile Therapeutics Receives Fast Track Designation for Cenderitide for Post-Acute Indication
March 9, 2011 Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors
February 28, 2011 Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
February 28, 2011 Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
September 13, 2010 Arno Therapeutics, Inc. Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds
June 17, 2010 Arno Therapeutics Announces Dosing of First Patient in a Phase I/IIa Study of AR-42, a broad spectrum histone and non-histone deacetylation inhibitor (pan-DAC)
December 17, 2009 Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 in Patients with Glioblastoma Multiforme (GBM)
December 15, 2009 Arno Therapeutics Announces Poster Presentation at ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity of AR-42
August 27, 2009 Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway
July 23, 2009 Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 (formerly DB-67) in Patients with Myelodysplastic Syndrome
May 11, 2009 FDA Accepts Arno Therapeutics’ IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
